Saccharomyces boulardii Improves Intestinal Epithelial Cell Restitution by Inhibiting αvβ5 Integrin Activation State

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Canonici, Alexandra ^a,b   Pellegrino, Emilie ^a,b   Siret, Carole ^a,b   Terciolo, Chloé ^a,b   Czerucka, Dorota ^c   Bastonero, Sonia ^a,b   Marvaldi, Jacques ^a,b   Lombardo, Dominique ^a,b   Rigot, Véronique ^a,b   André, Frédéric ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSERM   (France)

^c CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; PROBIOTIC AGENT; UVOMORULIN; VITRONECTIN;

ADHESION; ALPHAVBETA5 INTEGRIN SIGNALING PATHWAY; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL MIGRATION; CELL RESTITUTION; CONTROLLED STUDY; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SACCHAROMYCES BOULARDII; SIGNAL TRANSDUCTION;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; ENTEROCYTES; FEEDING BEHAVIOR; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, VITRONECTIN; SACCHAROMYCES; SIGNAL TRANSDUCTION; VITRONECTIN;

SACCHAROMYCES BOULARDII;

EID: 84866641415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045047     Document Type: Article

References (53)

1. Blikslager AT, Moeser AJ, Gookin JL, Jones SL, Odle J, (2007) Restoration of barrier function in injured intestinal mucosa. Physiol Rev 87: 545-564.
2. Mumy KL, Chen X, Kelly CP, McCormick BA, (2008) Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. Am J Physiol Gastrointest Liver Physiol 294: G599-609.
3. Martins FS, Dalmasso G, Arantes RM, Doye A, Lemichez E, et al. (2010) Interaction of Saccharomyces boulardii with Salmonella enterica serovar Typhimurium protects mice and modifies T84 cell response to the infection. PLoS ONE 5: e8925.
4. Sturm A, Dignass AU, (2008) Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol 14: 348-353.
5. Swanson PA 2nd, Kumar A, Samarin S, Vijay-Kumar M, Kundu K, et al. (2011) Enteric commensal bacteria potentiate epithelial restitution via reactive oxygen species-mediated inactivation of focal adhesion kinase phosphatases. Proc Natl Acad Sci U S A 108: 8803-8808.
6. Goke M, Kanai M, Lynch-Devaney K, Podolsky DK, (1998) Rapid mitogen-activated protein kinase activation by transforming growth factor alpha in wounded rat intestinal epithelial cells. Gastroenterology 114: 697-705.
7. Basson MD, (2001) In vitro evidence for matrix regulation of intestinal epithelial biology during mucosal healing. Life Sci 69: 3005-3018.
8. Zhang J, Owen CR, Sanders MA, Turner JR, Basson MD, (2006) The motogenic effects of cyclic mechanical strain on intestinal epithelial monolayer wound closure are matrix dependent. Gastroenterology 131: 1179-1189.
9. Basson MD, Modlin IM, Madri JA, (1992) Human enterocyte (Caco-2) migration is modulated in vitro by extracellular matrix composition and epidermal growth factor. J Clin Invest 90: 15-23.
10. Basson MD, Rashid Z, Turowski GA, West AB, Emenaker NJ, et al. (1996) Restitution at the cellular level: regulation of the migrating phenotype. Yale J Biol Med 69: 119-129.
11. Gilcrease MZ, (2007) Integrin signaling in epithelial cells. Cancer Lett 247: 1-25.
12. Lussier C, Basora N, Bouatrouss Y, Beaulieu JF, (2000) Integrins as mediators of epithelial cell-matrix interactions in the human small intestinal mucosa. Microsc Res Tech 51: 169-178.
13. Dignass AU, (2001) Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 7: 68-77.
14. Czerucka D, Piche T, Rampal P, (2007) Review article: yeast as probiotics - Saccharomyces boulardii. Aliment Pharmacol Ther 26: 767-778.
15. Canonici A, Siret C, Pellegrino E, Pontier-Bres R, Pouyet L, et al. (2011) Saccharomyces boulardii improves intestinal cell restitution through activation of the alpha2beta1 integrin collagen receptor. PLoS ONE 6: e18427.
16. Pothoulakis C, (2009) Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther 30: 826-833.
17. Buts JP, De Keyser N, (2010) Transduction pathways regulating the trophic effects of Saccharomyces boulardii in rat intestinal mucosa. Scand J Gastroenterol 45: 175-185.
18. McFarland LV, (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16: 2202-2222.
19. Plein K, Hotz J, (1993) Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea-a pilot study. Z Gastroenterol 31: 129-134.
20. Guslandi M, Giollo P, Testoni PA, (2003) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15: 697-698.
21. Girard P, Pansart Y, Coppe MC, Gillardin JM, (2005) Saccharomyces boulardii inhibits water and electrolytes changes induced by castor oil in the rat colon. Dig Dis Sci 50: 2183-2190.
22. Dalmasso G, Loubat A, Dahan S, Calle G, Rampal P, et al. (2006) Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells. Res Microbiol 157: 456-465.
23. Mammen JM, Matthews JB, (2003) Mucosal repair in the gastrointestinal tract. Crit Care Med 31: S532-537.
24. Andre F, Rigot V, Thimonier J, Montixi C, Parat F, et al. (1999) Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 83: 497-505.
25. Vermeulen SJ, Bruyneel EA, Bracke ME, De Bruyne GK, Vennekens KM, et al. (1995) Transition from the noninvasive to the invasive phenotype and loss of alpha-catenin in human colon cancer cells. Cancer Res 55: 4722-4728.
26. Chen X, Kokkotou EG, Mustafa N, Bhaskar KR, Sougioultzis S, et al. (2006) Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem 281: 24449-24454.
27. Canonici A, Steelant W, Rigot V, Khomitch-Baud A, Boutaghou-Cherid H, et al. (2008) Insulin-like growth factor-I receptor, E-cadherin and alpha v integrin form a dynamic complex under the control of alpha-catenin. Int J Cancer 122: 572-582.
28. Gorvel JP, Ferrero A, Chambraud L, Rigal A, Bonicel J, et al. (1991) Expression of sucrase-isomaltase and dipeptidylpeptidase IV in human small intestine and colon. Gastroenterology 101: 618-625.
29. Defilles C, Montero MP, Lissitzky JC, Rome S, Siret C, et al. (2011) alphav integrin processing interferes with the cross-talk between alphavbeta5/beta6 and alpha2beta1 integrins. Biol Cell 103: 519-529.
30. Defilles C, Lissitzky JC, Montero MP, Andre F, Prevot C, et al. (2009) alphavbeta5/beta6 integrin suppression leads to a stimulation of alpha2beta1 dependent cell migration resistant to PI3K/Akt inhibition. Exp Cell Res 315: 1840-1849.
31. Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC, (2011) Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol 301: G1083-1092.
32. Singh B, Su YC, Riesbeck K, (2010) Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol 78: 545-560.
33. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ, (2003) Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349: 350-357.
34. Zeeh JM, Procaccino F, Hoffmann P, Aukerman SL, McRoberts JA, et al. (1996) Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 110: 1077-1083.
35. Ido A, Numata M, Kodama M, Tsubouchi H, (2005) Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol 40: 925-931.
36. Chantret I, Rodolosse A, Barbat A, Dussaulx E, Brot-Laroche E, et al. (1994) Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line Caco-2: evidence for glucose-dependent negative regulation. J Cell Sci 107 (Pt 1): 213-225.
37. Kricker JA, Towne CL, Firth SM, Herington AC, Upton Z, (2003) Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin. Endocrinology 144: 2807-2815.
38. Avraamides CJ, Garmy-Susini B, Varner JA, (2008) Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617.
39. Hallstrom T, Blom AM, Zipfel PF, Riesbeck K, (2009) Nontypeable Haemophilus influenzae protein E binds vitronectin and is important for serum resistance. J Immunol 183: 2593-2601.
40. Chavakis T, Kanse SM, Lupu F, Hammes HP, Muller-Esterl W, et al. (2000) Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 96: 514-522.
41. Preissner KT, Reuning U, (2011) Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 37: 408-424.
42. Banno A, Ginsberg MH, (2008) Integrin activation. Biochem Soc Trans 36: 229-234.
43. Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B, (2007) Functional atlas of the integrin adhesome. Nat Cell Biol 9: 858-867.
44. Owen KA, Abshire MY, Tilghman RW, Casanova JE, Bouton AH, (2010) FAK regulates intestinal epithelial cell survival and proliferation during mucosal wound healing. PLoS ONE 6: e23123.
45. André F, Rigot V, Thimonier J, Montixi C, Parat F, et al. (1999) Integrins and E-cadherin cooperate with IGF-I to induce migration of epithelial colonic cells. Int J Cancer 83: 497-505.
46. Adair JE, Stober V, Sobhany M, Zhuo L, Roberts JD, et al. (2009) Inter-alpha-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding. J Biol Chem 284: 16922-16930.
47. Upton Z, Wallace HJ, Shooter GK, van Lonkhuyzen DR, Yeoh-Ellerton S, et al. (2011) Human pilot studies reveal the potential of a vitronectin: growth factor complex as a treatment for chronic wounds. Int Wound J 8: 522-532.
48. Huttenlocher A, Horwitz AR, (2011) Integrins in cell migration. Cold Spring Harb Perspect Biol 3: a005074.
49. Palecek SP, Loftus JC, Ginsberg MH, Lauffenburger DA, Horwitz AF, (1997) Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature 385: 537-540.
50. Buts JP, (2009) Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. Dig Dis Sci 54: 15-18.
51. Zanello G, Meurens F, Berri M, Salmon H, (2009) Saccharomyces boulardii effects on gastrointestinal diseases. Curr Issues Mol Biol 11: 47-58.
52. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, et al. (2006) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343: 69-76.
53. Lee SK, Kim HJ, Chi SG, Jang JY, Nam KD, et al. (2005) [Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells]. Korean J Gastroenterol 45: 328-334.